
Bio-Rad Laboratories has seen its share price move around sharply over different time frames, which puts a spotlight on whether the current US$388.31 level lines up with the cash the business is expected to generate. With fresh news on operations and asset use in play, the key issue for you is whether those cash flows can justify where the stock trades today.
For investors, the debate is whether Bio-Rad Laboratories' current share price is properly explained by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.
If you are weighing whether Bio-Rad Laboratories' US$388.31 price fairly reflects its cash flows, it can help to compare it with a broader set of 33 high quality undervalued stocks.
The Discounted Cash Flow (DCF) approach here looks at the cash Bio-Rad Laboratories can return to shareholders over time and discounts it back to today. Latest twelve month free cash flow sits around $306 million, and the projections used in this 2 Stage Free Cash Flow to Equity model assume that free cash flow grows steadily into the early 2030s rather than swinging sharply up or down.
On those assumptions, the DCF output suggests an intrinsic value that is meaningfully below the current US$388.31 share price. This points to the market assigning a richer price tag than these cash flow estimates alone might support. Because Elliott Investment Management is pushing for better margins and potential monetisation of the Sartorius stake, some of that gap can be read as investors already baking in the possibility of value being surfaced beyond the current free cash flow profile. Find out what Bio-Rad Laboratories could be worth using our Discounted Cash Flow (DCF) estimate.
Bio-Rad Laboratories' valuation puzzle highlights the role of Simply Wall St Narratives, which outline the paths for growth, margins and earnings that would need to hold for the shares to be worth meaningfully more or less than today based on cash flow assumptions, and these sit on the Community page. Each narrative links a fair value view to a clear storyline about Bio-Rad Laboratories' possible catalysts and key risks so you can track which scenario appears to be unfolding over time.
Bullish and bearish narratives around Bio-Rad Laboratories are pulling in opposite directions, with one side seeing upside and the other seeing downside risk.
Bull case: 12% undervalued
This view comes from the bullish analyst narrative on Simply Wall St, which leans on margin recovery and platform focus.
"Execution on repeated restructuring, including operating expense, facility and distribution center rationalization and IT and commercial efficiencies that are expected to provide US$30 million to US$35 million of net annual cost savings by the end of 2027, gives Bio-Rad Laboratories an underappreciated opportunity to convert flat or modest revenue changes into higher operating margin and earnings power…"
Discover why this Narrative puts Bio-Rad Laboratories at 12% undervalued.
Bear case: 16% overvalued
This view comes from the analyst consensus narrative on Simply Wall St, which focuses more on concentration and execution risk.
"Continued focus on Droplet Digital PCR platforms, including the contribution from Stilla Technologies, is expected to keep ddPCR instruments growing from an already strong base of three consecutive quarters of more than 20% year-over-year instrument growth…"
Explore why this Narrative puts Bio-Rad Laboratories at 16% overvalued.
Who is steering Bio-Rad Laboratories and how their pay lines up with your interests can be just as important as any cash flow model, and that question still needs answering. See who runs Bio-Rad Laboratories and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com